STING activation and overcoming the challenges associated with STING agonists using ADC (antibody-drug conjugate) and other delivery systems
Authors:
- 6 February 2025
- journal article
- review article
- Published by Elsevier in Cellular Signalling
- Vol. 128, 111647
Abstract
No abstract availableKeywords
Funding Information
- University Grants Commission
This publication has 132 references indexed in Scilit:
- Combination of IFN-gamma with STING agonist and PD-1 immune checkpoint blockade: a potential immunotherapy for gastric cancerMedical Oncology, 2024
- Tumor Exosomal ENPP1 Hydrolyzes cGAMP to Inhibit cGAS‐STING SignalingAdvanced Science, 2024
- Type I interferon-mediated tumor immunity and its role in immunotherapyCellular and Molecular Life Sciences, 2022
- RETRACTED ARTICLE: The analog of cGAMP, c-di-AMP, activates STING mediated cell death pathway in estrogen-receptor negative breast cancer cellsApoptosis, 2021
- Review of immune checkpoint inhibitors in immuno-oncology2021
- Metalloimmunology: The metal ion-controlled immunity2020
- MHC/HLA Class I Loss in Cancer Cells2019
- Delivering safer immunotherapies for cancerAdvanced Drug Delivery Reviews, 2017
- The Chemistry of the Noncanonical Cyclic Dinucleotide 2′3′-cGAMP and Its Analogs2015
- Myeloid-derived suppressor cells in breast cancerBreast Cancer Research and Treatment, 2013